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The use of monoclonal antibodies (mAbs) for cancer therapy is one of the most important strategies for
current cancer treatment. The epidermal growth factor receptor (EGFR) family of receptor tyrosine ki-
nases, which regulates cancer cell proliferation, survival, and migration, is a major molecular target for
antibody-based therapy. ErbB4/HER4, which contains a ligand-binding extracellular region, is activated
by several ligands, including neuregulins (NRGs), heparin-binding EGF-like growth factor, betacellulin
and epiregulin. Although there are clinically approved antibodies for ErbB1 and ErbB2, there are no
available therapeutic mAbs for ErbB4, and it is not known whether ErbB4 is a useful target for antibody-
based cancer therapy. In this study, we developed an anti-ErbB4 mAb (clone P6-1) that suppresses NRG-
dependent activation of ErbB4 and examined its effect on breast cancer cell proliferation in the extra-
cellular matrix.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The epidermal growth factor receptor (EGFR) family of receptor
tyrosine kinases consists of ErbB1 (also known as EGFR and HER1),
ErbB2 (c-Neu, HER2), ErbB3 (HER3), and ErbB4 (HER4). The acti-
vation of the ErbB receptors stimulates intracellular signaling
pathways, including the RAS-RAF-MEK-ERK, PI3K-AKT, and JAK-
STAT pathways, that promote cell proliferation, survival, and
migration. Therefore, aberrant activation of ErbB receptors is
frequently observed in multiple types of human cancers [1].
ErbB4 is a 180 kDa glycoprotein consisting of a ligand-binding
extracellular region, a transmembrane region, and a cytoplasmic
region containing a tyrosine kinase domain. ErbB4 is activated by
the ligands neuregulin 1-4 (NRG1-4) [2e5], heparin-binding EGF
(HB-EGF) [6], betacellulin [7], and epiregulin [8], and forms homo-
or heterodimers with other EGFR family proteins. Recently, ErbB4
was shown to play an essential role in the development and
maintenance of the heart, mammary glands, and nervous system
[9e12]. Expression of ErbB4 affects the growth of human breasto).
Inc. This is an open access article ucancer cells [13], and it transformsmouse mammary epithelial cells
in vitro and in vivo [14]. On the other hand, stimulation of breast
cancer cells with NRG-1 suppresses cell growth in an ErbB4-
dependent manner [15,16]. Thus, little is known about the func-
tional relevance of ErbB4 to the behavior of cancer cells.
The use of monoclonal antibodies (mAbs) to block oncogenic
receptors is an established mode of cancer therapy [17]. However,
despite the clinical success of ErbB1 and ErbB2 antibodies, it is
unknown whether ErbB4 is a useful molecular target for antibody-
based cancer therapy. To examine this possibility, we established a
novel human ErbB4 antibody that blocks NRG-1-ErbB4 signaling
and examined its effect on cancer cells.2. Results
2.1. Generation of human ErbB4-speciﬁc mAbs
To examine the functional role of ErbB4 in cancer cells, a mAb
against human ErbB4 (anti-ErbB4 mAb) was generated. First, rat
hepatoma RH7777 cells stably expressing GFP-tagged ErbB4
(ErbB4-GFP) were generated; then, F344/N rats were immunized
with the cells several times. After conﬁrmation of a raised antibody
titer in immunized rat serum, spleen-derived lymphocytes werender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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cell lines secreting ErbB4 mAbs were obtained (Fig. 1A).
To analyze the speciﬁcity of the anti-ErbB4 mAbs, their reac-
tivity to GFP-tagged ErbB1-, ErbB2-, ErbB3-, or ErbB4-expressing
RH7777 cells was evaluated by ﬂow cytometry. The anti-ErbB4
mAbs (P6-1, P32-1, 1e3C, and 3e10A) were found to bind
strongly to the ErbB4-expressing RH7777 cells in a GFP expression
level-dependent manner, and had low or negligible reactivity to the
other ErbB family members (Fig. 1B). These results indicate that the
four newly developed anti-ErbB4 mAbs are speciﬁc for the human
ErbB4 protein.
2.2. ErbB4 expression analysis on various cancer cell lines
Flow cytometry was next performed to examine the reactivity of
the four anti-ErbB4 mAbs to various human cancer cell lines. Using
the clone P6-1, which exhibited the strongest reactivity to ErbB4,
we found that ErbB4 was highly expressed on breast cancer cell
lines compared with other types of cancer cells (Fig. 2). As previ-
ously reported [18], the estrogen receptor-positive breast cancer
cell lines T47D and MCF7 were found to have the higher ErbB4
expression among the breast cancer cell lines (Fig. 2). Furthermore,
esophageal cancer (TE1), bladder cancer (KU-1), lymphoma (Raji),
and embryonic kidney (HEK293F) cells also expressed high levels of
ErbB4 (Fig. 2). These results indicate that ErbB4 is differentiallyFig. 1. Development of ErbB4-speciﬁc monoclonal antibodies. A. Schema for immunization
expressing RH7777 cells were incubated with indicated mAbs followed by the staining wi
metric analysis. PE and GFP ﬂuorescence intensities are plotted on the vertical and horizon
with ErbB1, ErbB2 and ErbB3-expressing RH7777 cells respectively, whereas anti-ErbB4 mAexpressed in human cancer cell lines.2.3. Inhibition of ligand-dependent ErbB4 phosphorylation with
anti-ERBB4 mAbs
Given that the development of blocking antibodies is a thera-
peutic strategy for cancer treatment, we examined whether the
newly developed ErbB4 mAbs are able to inhibit ligand-dependent
ErbB4 phosphorylation (activation) in cancer cells. Addition of
neuregulin-1 (NRG-1), a known ligand for ErbB4, to the culture
medium strongly induced ErbB4 phosphorylation in T47D cells,
which expressed high levels of ErbB4 (Fig. 3A), suggesting that
NRG-1 acts as a ligand for ErbB4 in these cells. Pre-treatment of the
cells with the anti-ErbB4 mAb P6-1, but not P32-1, 1e3C, or 3e10A,
signiﬁcantly reduced the NRG-1-dependent phosphorylation of
ErbB4 in T47D cells (Fig. 3A), suggesting that P6-1 may block NRG-
1-induced ErbB4 signaling.
To further examinewhether P6-1 acts as a neutralizing antibody
for ErbB4, the effect of NRG-1 was examined on another breast
cancer cell line, MCF7. Treatmentwith P6-1 strongly suppressed the
NRG-1-induced activation of ErbB4 in a concentration-dependent
manner (Fig. 3B). These results suggest that P6-1 acts as a
neutralizing antibody for ErbB4 in cancer cells.and hybridoma development. B. Stably GFP-tagged ErbB1-, ErbB2-, ErbB3-, or ErbB4-
th PE-conjugated anti-rat IgG secondary antibodies and were subjected to ﬂow cyto-
tal axes, respectively. Note that anti-ErbB1, ErbB2 and ErbB3 mAbs speciﬁcally reacted
bs speciﬁcally reacted with ErbB4- expressing RH7777 cells.
Fig. 2. Flow cytometric analysis of cell surface ErbB4 expression on various human cell lines. The indicated cell lines were stained with anti-ErbB4 mAb clone P6-1 and a PE-
conjugated anti-rat IgG. Data are the mean ﬂuorescence intensities (MFI) minus the MFI of the control (cells stained with the secondary antibody only).
Fig. 3. The anti-ErbB4 monoclonal antibody P6-1 inhibits NRG-1-induced ErbB4
phosphorylation. A. T47D cells were serum-starved for 3 h, cultured in the presence or
absence of anti-ErbB4 mAbs (10 mg/mL) for 10 min, and then stimulated with NRG-1
(10 ng/mL) for 10 min. Cells were lysed and subjected to immunoblot analysis. Total
ErbB4 was analyzed as a loading control. B. MCF7 cells were serum-starved for 3 h, and
then incubated with anti-ErbB4 mAb clone P6-1 at the indicated concentrations for
10 min, followed by stimulation with NRG-1 (10 ng/mL) for 10 min. Cells were lysed
and subjected to immunoblot analysis. Total ErbB4 was analyzed as a loading control.
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breast cancer cells
Given that ErbB signaling is implicated in cell survival, prolif-
eration, and differentiation [19], we examined whether the anti-
ErbB4 mAb P6-1 suppresses colony formation by breast cancer
cells in three-dimensional (3D) culture conditions. In the 3D culture
system, NRG-1 increased the size of colonies formed by MCF7 cells
(Fig. 4A and B), suggesting that NRG-1 promotes breast cancer cell
proliferation. However, the NRG-1 dependent increase in colony
size was signiﬁcantly suppressed in the presence of P6-1 (Fig. 4A
and B), suggesting that NRG-1-induced proliferation of breast
cancer cells is partly mediated by ErbB4 signaling.3. Discussion
Antibody-mediated killing of cancer cells can be achieved
through the direct action of the antibody or through immune-
mediated mechanisms [17]. Direct actions of the antibody include
receptor blockade or agonist activity, induction of apoptosis, or
delivery of a drug or cytotoxic agent. On the other hand, immune-
mediated cancer cell killing includes complement-dependent
cytotoxicity, antibody-dependent cellular cytotoxicity, and the
regulation of T cell function. Recently, the therapeutic beneﬁt of an
ErbB1-targeting mAb (cetuximab) and ErbB2-targeting mAb (tras-
tuzumab) was demonstrated clinically [1]. However, a therapeutic
mAb that can inhibit ligand-induced activation of ErbB4 has not yet
Fig. 4. Growth inhibition of MCF7 breast cancer cells by the anti-ErbB4 mAb P6-1 in a three-dimensional culture. A. MCF7 cells were cultured on Matrigel-coated slides with or
without NRG-1 (10 ng/mL) and P6-1 (30 mg/mL) for 4 days. Colonies were stained with Hoechst 33342 and visualized by ﬂuorescence microscopy. Phase-contrast and Hoechst 33342
ﬂuorescence (blue) merged images are shown. Scale bars, 200 mm. B. The number of colonies per ﬁeld of view with a diameter greater than 100 mm was determined. Data are the
mean ± SD of four ﬁelds of view (10 objective lens). **, P < 0.005.
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In the present study, we developed novel mAbs against the
human ErbB4 protein and examined ErbB4 expression in various
cancer cell lines. Consistent with previous reports [20], ErbB4 was
differentially expressed in human cancer cell lines and highly
expressed in breast cancer cell lines, including T47D and MCF7
cells. These results suggest that ErbB4 might play a role in breast
cancer development. Recently, ErbB4 was shown to mediate ac-
quired resistance to ErbB2 inhibitors in breast cancer cells [21].
Thus, ErbB4 signaling might become more important for the sur-
vival of ErbB2-positive breast cancer cells in the presence of ErbB2-
targeting mAbs.
Neuregulins (NRGs), a family of four structurally related proteins
that are members of the EGF family, bind to the EGFR family of
receptor tyrosine kinases, including ErbB3 and ErbB4, and activate
intracellular signaling, leading to cell proliferation, survival, and
differentiation. Recently, NRG-1-activated ErbB4 was shown to
interact with Yes-associated protein to activate Hippo pathway
target genes and promote breast cancer cell migration, suggesting
that NRG-1-ERBB4 signaling plays a key role in breast cancer pro-
gression [22]. Furthermore, NRG-1-mediated ErbB4 activation has
been shown to enhance the HIF-1a signaling in breast cancer cells
[23]. These results suggest that NRG-1-ErbB4 signaling plays a key
role in breast cancer progression. In this study, we examined the
effect of newly developed ErbB4 mAbs on NRG-1-induced ErbB4
activation and found that P6-1 is able to suppress ErbB4 activationin response to NRG-1 in breast cancer cells. Recently, ErbB4 has
been shown to undergo the ligand-dependent transmembrane
domain cleavage leading to the release of soluble 80-kDa intracel-
lular domain that modulates intracellular signaling [24]. However,
it remains unknown whether the phosphorylation status of ErbB4
impacts the activity of ErbB4 cleavage leading to the release of
soluble intracellular domain. Further investigations on the effect of
P6-1 on ErbB4 cleavage in cancer cells are warranted.
Finally, we examined whether P6-1 suppresses colony forma-
tion byMCF7 breast cancer cells on a 3Dmatrix. Treatment with P6-
1 signiﬁcantly suppressed NRG-1-induced growth of MCF7 col-
onies, although P6-1 did not affect cell proliferation under standard
in vitro culture conditions (data not shown). These data suggest that
several types of breast cancer might utilize and depend on ErbB4
signaling, which mediates NRG-1-dependent breast cancer cell
proliferation in vivo.
Therefore, our newly developed ErbB4 mAb might be useful for
the treatment of ErbB4-expressing cancers.4. Materials and methods
4.1. Cell culture
Human leukemia cells (CCRF-SB, Jurkat, K562, Raji, and U937)
and mouse myeloma cells (P3U1 and X63) were cultured in RPMI
1640 medium (SigmaeAldrich, St. Louis, MO, USA). Human tumor
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NCIeH292, NCIeH647, and NCIeH1395), esophageal (TE-1, TE-2,
TE-3, TE-4, TE-5, TE-12, TE-13 and TE-14), breast (BT20, BT474,
MCF7, SK-Br-3, T47D, ZR-75e1, and MDA-MB-231), liver (HepG2
and Hep3B), stomach (KATO III and MKN28), colon (HCT116, LS-
174T, and SW1116), epidermoid (A431), cervix (HeLa and ME180),
ovary (SK-OV-3), prostate (PC-3), kidney (ACHN), and bladder (T24
and KU-1)] and HEK293F human embryonic kidney cells (Ther-
moFisher Scientiﬁc, Waltham, MA, USA), as well as Int407 embry-
onic intestinal cells and RH7777 rat hepatoma cells were cultured
in Dulbecco's modiﬁed Eagle's medium (SigmaeAldrich) supple-
mented with 7% heat-inactivated fetal bovine serum (FBS; ICN
Biomedicals, Aurora, OH, USA) in a humidiﬁed incubator (5% CO2) at
37 C. RH7777 rat hepatoma cells were kindly donated by Mitsu-
bishi Tanabe Pharma, Yokohama, Japan.
4.2. Plasmid construction and transfection
JM-a CYT-2 isoform of ErbB4 complementary DNAs (cDNAs) was
cloned from LK-4 cell. ErbB1 were cloned from A431 cells. ErbB2
and ErbB3 were cloned from SK-BR-3 cells. GFP was genetically
fused to the carboxyl terminus of full-length or extracellular region
of ErbB1, ErbB2, ErbB3, or ErbB4 in the pAcGFP expression vector.
RH7777 cells were transfected with these expression vectors using
Lipofectamine 2000 (ThermoFisher), selected in G418-containing
medium (400 mg/mL), and sorted for cellular GFP ﬂuorescence
with a JSAN cell sorter (Bay Bioscience, Kobe, Japan).
4.3. Development of anti-ErbB1, 2, 3, and 4 mAbs
Female F344/N rats were injected with RH7777 cells expressing
GFP-tagged human ErbB1, 2, 3, or 4 subcutaneously and intraperi-
toneally several times at 2 week intervals. Three days after the ﬁnal
immunization, splenocytes of immunized rats were isolated and
fused with X63 or P3U1 mouse myeloma cells using 50% poly-
ethylene glycol 1540 (Roche Diagnostics). After the cell fusion,
hybridoma cells were selected in 7% FBS-containing RPMI 1640
medium (Sigma) containing hypoxanthine, aminopterin, and
thymidine (HAT supplement; ThermoFisher Scientiﬁc). The hy-
bridomas were primarily screened with enzyme linked immuno
solvent assay (ELISA) against recombinant GFP fused extracellular
ErbB1, ErbB2 or ErbB3 protein, or sandwich-ELISA using anti-GFP
rabbit polyclonal antibody as capture antibody and GFP fused
ErbB4 expressing HEK293F lysate as antigen with the use of hy-
bridoma culture supernatant. As a secondary screening, reactivity
for GFP fused ErbB1, ErbB2, ErbB3 or ErbB4 expressing HEK293F
cells was analyzed with ﬂow cytometry analysis. mAbs secreted by
hybridoma cells were puriﬁed as previously described [25].
4.4. Animals
Female F344/N rats were obtained from the Shimizu Animal
Farm (Kyoto, Japan). They were bred and maintained in the animal
facility at Kinki University according to institutional guidelines.
4.5. Antibodies
Anti-ErbB4 and phosphorylated ErbB4 mAbs for immunoblot
analysis were obtained from Cell Signaling Technologies (Manassas,
VA, USA; #4795 and #4757).
4.6. Flow cytometry
For staining of cell surface antigens, cells were incubated with
10 mg/mL of primary antibodies for 30 min at 4 C, followed byincubation with secondary antibodies labeled with phycoerythrin
(PE) for 30min. Cells were analyzed on an Accuri C6 ﬂow cytometer
(BectoneDickinson, Sunnyvale, CA, USA).
4.7. Immunoblot analysis
Cells were lysed with 2 Laemmli buffer containing 0.1 M DTT.
Equal amounts of lysed protein were separated by SDS-PAGE,
transferred to PVDF membranes, and incubated with antibodies.
Immunocomplexes were detected with a peroxidase-conjugated
secondary antibody and Chemiluminescence Reagent Plus (Per-
kineElmer, Waltham, MA, USA).
4.8. 3D culture
3D culture was performed with some modiﬁcations of a previ-
ously described procedure [26]. MCF7 cells (1  104) were seeded
on Matrigel (BD Biosciences, San Jose, CA, USA)-coated eight-well
chamber slides with or without 10 ng/mL NRG-1 (Peprotech, Rocky
Hill, NJ, USA) in the presence or absence of anti-ErbB4 mAb clone
P6-1 (30 mg/mL) for 4 days, followed by staining with Hoechst
33342. Phase-contrast and ﬂuorescent images were acquired by
ﬂuorescent microscopy, and the number of colonies per ﬁeld of
view with a diameter greater than 100 mm was determined.
4.9. Statistical analysis
Data are presented as the means ± SD and were analyzed by the
unpaired Student's t-test using Excel 2013 (Microsoft). A P-value of
<0.05 was considered statistically signiﬁcant.
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